Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Clene Inc.

Market Cap 70.66M 61.32M 56.53M 52.96M 98.96M 6.77B 101M 674M 261M 3.26B 265M 260M 11.34B P/E Ratio 2026 *
-3.1x
P/E Ratio 2027 * -3.76x
Enterprise Value 57.26M 49.69M 45.81M 42.92M 80.19M 5.48B 81.86M 546M 212M 2.64B 215M 210M 9.19B EV / Sales 2026 *
276x
EV / Sales 2027 * 2.08x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day+0.55%
1 week-4.98%
Current month-15.70%
1 month-14.92%
3 months-0.90%
6 months-19.62%
Current year-5.79%
1 week 5.25
Extreme 5.25
5.72
1 month 5.25
Extreme 5.25
7.37
Current year 3.88
Extreme 3.88
8.67
1 year 3.25
Extreme 3.25
13.5
3 years 2.28
Extreme 2.2801
21.8
5 years 2.28
Extreme 2.2801
356.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 2013-03-31
Chief Tech/Sci/R&D Officer 67 2012-12-31
Director of Finance/CFO 57 2022-01-31
Director TitleAgeSince
Chairman 65 2015-10-31
Director/Board Member 53 2019-08-31
Director/Board Member 49 2020-11-30
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

3,728 0.0317%
05-20
MatlinPatterson Global Advisers LLC
FreeCompany 5,159 0.0438%
05-20Free

Director

3,658 0.0311%
Change 5-day change 1-year change 3-year change Capi.($)
+0.55%-4.98%+31.67%-73.16% 70.66M
+1.65%+6.42%+53.16%+112.78% 55.58B
+0.03%+0.33%+49.22%+43.94% 43.47B
+3.93%-0.06%-15.10%-18.04% 22.64B
+5.27%-7.82%-1.29%+388.48% 20.96B
+3.01%-5.86%+11.06%-30.11% 15.79B
+0.53%+2.08%+8.89%-39.59% 15.3B
+1.75%+1.92%+29.13%+178.65% 13.45B
+8.67%+8.95%+17.94% - 11.74B
-5.27%-0.43%+87.77%+208.02% 10.96B
Average +2.00%-0.88%+27.25%+85.66% 21B
Weighted average by Cap. +1.97%+0.76%+31.45%+98.42%

Financials

2026 *2027 *
Net sales 207K 180K 166K 155K 290K 19.86M 296K 1.98M 766K 9.57M 779K 762K 33.28M 23.64M 20.52M 18.91M 17.72M 33.11M 2.26B 33.8M 226M 87.35M 1.09B 88.76M 86.85M 3.79B
Net income -25.09M -21.78M -20.07M -18.81M -35.14M -2.4B -35.87M -239M -92.71M -1.16B -94.2M -92.17M -4.03B -27.55M -23.91M -22.04M -20.65M -38.58M -2.64B -39.38M -263M -102M -1.27B -103M -101M -4.42B
Net Debt -13.4M -11.63M -10.72M -10.04M -18.77M -1.28B -19.16M -128M -49.5M -618M -50.3M -49.22M -2.15B -21.4M -18.57M -17.12M -16.04M -29.97M -2.05B -30.59M -204M -79.06M -988M -80.34M -78.6M -3.43B
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
78
Date Price Change Volume
26-06-11 5.530 $ +0.55% 72,416
26-06-10 5.500 $ -1.26% 125,451
26-06-09 5.570 $ +4.50% 103,582
26-06-08 5.330 $ -2.20% 87,009
26-06-05 5.450 $ -6.36% 114,659
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.530USD
Average target price
32.20USD
Spread / Average Target
+482.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!